lorazepam and gemfibrozil

lorazepam has been researched along with gemfibrozil in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (57.14)29.6817
2010's3 (42.86)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T1
He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Deguchi, T; Furuta, Y; Fusegawa, K; Hirouchi, M; Igeta, K; Ikenaga, H; Iwasaki, M; Izumi, T; Kurihara, A; Murata, S; Okazaki, O; Suzuki, N; Watanabe, N1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Konishi, K; Minematsu, T; Nagasaka, Y; Tabata, K1

Reviews

1 review(s) available for lorazepam and gemfibrozil

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

6 other study(ies) available for lorazepam and gemfibrozil

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
    Journal of medicinal chemistry, 2008, Jul-10, Volume: 51, Issue:13

    Topics: Anilino Naphthalenesulfonates; Animals; Fatty Acid-Binding Proteins; Ligands; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Fluorescence; Substrate Specificity

2008
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:4

    Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software

2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:5

    Topics: Administration, Oral; Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Area Under Curve; Cytochrome P-450 Enzyme System; Dogs; Drug Evaluation, Preclinical; Glucuronides; Glucuronosyltransferase; Half-Life; Humans; Macaca fascicularis; Male; Mice; Pharmaceutical Preparations; Predictive Value of Tests; Rats; Rats, Sprague-Dawley; Species Specificity

2011
Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment.
    Biopharmaceutics & drug disposition, 2019, Volume: 40, Issue:5-6

    Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aging; Butyrylcholinesterase; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Desipramine; Drug Interactions; Female; Gemfibrozil; Glucuronosyltransferase; Humans; Itraconazole; Lorazepam; Male; Middle Aged; Models, Biological; Renal Insufficiency; Thiazoles; Young Adult; Zidovudine

2019